ET-1 may act via their receptors, ETAR and/or ETBR, in paracrine, endocrine or autocrine ways, activating many signaling pathways involved in cancer progression, including MAPK, NFκB, β-catenin, PI3K/Akt, PKC and Src [1, 5]. This evidence concerns the gene EDN1 and cancer.